Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Stock Information for Femasys Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Femasys Inc.

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Femasys Regains Compliance with Nasdaq Listing Requirements
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG(TM) Catheter
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.